Bristol-Myers Squibb Co. (BMY) Deucravacitinib Data Shows Superiority but Black Box Warning is Possible - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst David Risinger reiterated an Overweight rating and $70.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
